Sanofi forecast another year of revenue and earnings growth after sales of the French drugmaker’s blockbuster skin and asthma treatment Dupixent drove higher-than-expected profit in its latest quarter.
Earnings per share, excluding some items, were €1.53 in the fourth quarter, ahead of the €1.45 anticipated by analysts. Sanofi said sales would rise by a high single-digit percentage in 2026, with profit growing slightly faster.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.